Your missing links are here (30 October 2020)

Some of the best stuff we picked up around the internet

By: Gorm Palmgren - Oct. 30, 2020

Top Pick

Research

Delivery

Industry

Visions and Opinion

Clinical Trials

  • Rubius Therapeutics has presented preclinical data for RTX-321, a red cell therapeutic oncology product candidate for HPV-positive cancers. The data demonstrate that RTX-321 has a dual mechanism of action by not only functioning as an antigen-presenting cell to boost HPV 16 antigen-specific T cell responses but also promoting broad immune system stimulation of both innate and adaptive immunity.

COVID-19

Beyond Medicine

Tags

HashtagArticleHashtagMissing links

WeDoCRISPR™
close
Search CRISPR Medicine